Immunization and Vaccine-Preventable Diseases Practice Questions

Q: Which vaccine is associated with a risk of encephalopathy?

Measles. ***Measles*** - Among the options provided, **measles vaccine** has been reported to have a very rare association with **post-vaccination encephalitis/encephalopathy** (approximately 1 per million doses). - **Important note:** The **pertussis vaccine (particularly whole-cell DTP)** is the vaccine most classically associated with encephalopathy risk, but it is not among the options here. - The risk of encephalopathy from the measles vaccine is significantly lower than the risk from natural measles infection itself. - Modern measles vaccines are highly purified and safer than earlier formulations. *OPV* - **Oral Polio Vaccine (OPV)** is associated with **vaccine-associated paralytic poliomyelitis (VAPP)**, not encephalopathy. - VAPP occurs at a rate of approximately 1 case per 2.4 million doses due to reversion of the attenuated virus to a neurovirulent form. - Manifests as flaccid paralysis, not encephalopathy. *Rubella* - **Rubella vaccine** (component of MMR) is very safe with no significant association with encephalopathy. - Rare adverse effects include transient arthralgia (especially in adult women), mild rash, or lymphadenopathy. - Severe neurological complications are extremely rare. *BCG* - **Bacillus Calmette-Guérin (BCG) vaccine** protects against tuberculosis and is not associated with encephalopathy. - Common adverse effects are local reactions: induration, ulceration, scarring, and rarely lymphadenitis. - Disseminated BCG infection can occur in immunocompromised individuals but is distinct from encephalopathy.

Q: Ideal temperature for DPT storage?

4 to 8°C. ***4 to 8°C*** - The ideal temperature for DPT (diphtheria, pertussis, tetanus) vaccine storage is between **+2°C and +8°C** (or 35°F and 46°F), which is the standard refrigerator temperature range. - This temperature range is crucial for maintaining the **potency** and **efficacy** of the vaccine, preventing **degradation** due to excessive heat or cold. *Room temperature* - Storing DPT vaccines at **room temperature** (typically 20-25°C or 68-77°F) for extended periods can lead to a **loss of potency** as heat can degrade vaccine components. - While short-term excursions within this range might be permissible under specific conditions (e.g., during transport), it is not the ideal long-term storage solution. *0 to - 20°C* - DPT vaccines, particularly the **whole-cell pertussis (wP)** component, can be **damaged by freezing**. - Temperatures below 0°C can cause the **adjuvant** (usually aluminum salt) to separate, leading to a loss of efficacy and potential local reactions at the injection site. *None of the options* - This option is incorrect because **4 to 8°C** is indeed the established and recommended ideal storage temperature for DPT vaccines.

Q: Which of the following is the primary component of the AFP (Acute Flaccid Paralysis) case definition used in polio surveillance?

Onset of acute flaccid paralysis. ***Onset of acute flaccid paralysis*** - The primary component of the **AFP case definition** for polio surveillance is the acute onset of **flaccid paralysis** in a child under 15 years, or paralytic illness in a person of any age when polio is suspected. - This definition is crucial for identifying all potential cases of polio, regardless of the cause, to ensure thorough investigation and prevent outbreaks. *Stool specimen positive for poliovirus* - A positive stool specimen for poliovirus is a **laboratory confirmation** of polio infection, but it is not the primary component of the initial case definition. - The AFP case definition aims for **high sensitivity** to capture all possible cases for investigation, even before laboratory results are available. *Presence of residual paralysis after 60 days* - Residual paralysis after 60 days is an important indicator for **classifying a confirmed polio case** and understanding the long-term impact. - However, it is a **follow-up criterion** used after the initial detection of AFP, not the primary component that triggers the initial surveillance. *All of the above* - While laboratory confirmation and residual paralysis provide further information about a case, the **initial identification relies specifically on the clinical presentation** of acute flaccid paralysis. - The broad clinical definition ensures that no potential polio case is missed, initiating an immediate public health response.

Q: What is the appropriate diluent for the BCG vaccine?

Sterile distilled water. ***Sterile distilled water*** - **Sterile distilled water** is the recommended diluent for the **BCG vaccine** to ensure proper reconstitution and antigen stability. - Using the correct diluent is critical for maintaining the **efficacy** and safety of the vaccine. *Sterile normal saline* - **Sterile normal saline** (0.9% NaCl) can be used as a diluent for some vaccines, but it is **not appropriate for BCG** as it can negatively impact vaccine viability. - The **salt concentration** in saline can affect the live attenuated organisms in the BCG vaccine. *Sterile dextrose solution* - **Dextrose solutions** are generally avoided as vaccine diluents due to their potential to support **bacterial growth** or alter vaccine stability. - They are primarily used for **intravenous fluid administration** and not for vaccine reconstitution. *Colloid solutions* - **Colloid solutions** like albumin or dextran are never used as vaccine diluents as they can interfere with the **vaccine antigens** and cause adverse reactions. - These solutions are typically used for **plasma volume expansion** and have no role in vaccine preparation.

Q: Dukoral is:

Oral cholera vaccine. ***Oral cholera vaccine*** - Dukoral is a **killed oral whole-cell vaccine** against *Vibrio cholerae* O1 and O139, often combined with a recombinant B subunit of cholera toxin. - It provides protection against **cholera**, an acute diarrheal illness caused by bacterial infection of the small intestine. *Oral rotavirus vaccine* - Oral rotavirus vaccines (e.g., Rotarix, RotaTeq) provide protection against **rotavirus**, the most common cause of severe diarrhea in infants and young children. - These vaccines are usually given in multiple doses to infants and are distinct from cholera vaccines. *Oral typhoid vaccine* - An oral typhoid vaccine, such as Ty21a, is used for the prevention of **typhoid fever**, caused by *Salmonella Typhi*. - It is a **live attenuated vaccine** administered in several doses over a week, differing significantly from Dukoral's mechanism and target. *Ready to use therapeutic food* - **Ready-to-use therapeutic food (RUTF)** is a high-energy, micronutrient-rich paste used for the treatment of **severe acute malnutrition (SAM)**, especially in children. - It is a nutritional intervention, not a vaccine, and helps in weight gain and recovery for malnourished individuals.

Q: What are the serogroups covered by the bivalent meningococcal vaccine?

Serogroup A and C. ***Serogroup A and C*** - The **bivalent meningococcal vaccine** specifically targets and provides protection against **Neisseria meningitidis** serogroups **A and C**. - This vaccine is crucial for preventing invasive meningococcal disease caused by these prevalent strains, particularly in the African meningitis belt. - Examples include **meningococcal AC conjugate vaccines** used in mass vaccination campaigns. *Serogroup A* - While **Serogroup A** is one of the types covered by bivalent vaccines, it is not the only one. - A vaccine covering only Serogroup A would be a **monovalent vaccine**, not bivalent. *Serogroup W* - **Serogroup W** is covered by **quadrivalent meningococcal vaccines** (e.g., MenACWY) which protect against serogroups A, C, W, and Y. - It is **not included** in **bivalent** formulations. *Serogroup C* - While **Serogroup C** is one of the types covered by bivalent vaccines, it is not the only one. - A vaccine covering only Serogroup C would be a **monovalent vaccine**, not bivalent.

Q: What is the standard amount of diphtheria toxoid in the DT vaccine?

30 Lf. ***30 Lf*** - The **DT vaccine** (pediatric diphtheria-tetanus vaccine) contains **30 Lf** of **diphtheria toxoid** per dose according to traditional formulations, along with tetanus toxoid. - This higher diphtheria toxoid content is standardized for vaccines administered to children younger than 7 years. - Note: Modern vaccine standards often express potency in **International Units (IU)** where ≥30 IU corresponds to approximately 15-25 Lf, though 30 Lf was the traditional specification. *5 Lf* - This reduced amount of diphtheria toxoid is present in adult formulations like **Tdap vaccine** and **Td vaccine** (typically 2-5 Lf). - The lower diphtheria toxoid content in adult vaccines is sufficient to maintain immunity in individuals with pre-existing immunity from childhood vaccination. *10 Lf* - This amount of diphtheria toxoid is not a standard specification for DT, Td, or Tdap vaccines. - Standard diphtheria toxoid amounts are typically 15-30 Lf for pediatric formulations (DT/DTP) and 2-5 Lf for adult formulations (Td, Tdap). *15 Lf* - While approximately 15 Lf may correspond to the minimum potency when measured in International Units (≥30 IU), the traditional standard specification for DT vaccine is **30 Lf**. - Vaccine formulations are precisely standardized to ensure optimal immunogenicity and safety.

Q: At what age can the measles vaccine be administered for the first time in high-risk scenarios or outbreak situations?

At 6 months. ***At 6 months*** - In situations of **high risk** or **outbreaks**, the measles vaccine can be given as early as **6 months of age**. - This early dose is considered an extra dose and does not count towards the routine vaccination schedule; a child would still need to receive the standard doses at 12-15 months and 4-6 years. *3 to 5 months* - The measles vaccine is generally not recommended before **6 months of age** because the presence of **maternal antibodies** can interfere with the vaccine's effectiveness. - Vaccinating at this age would likely result in an inadequate immune response. *5 to 6 months* - While closer to the recommended age for high-risk situations, the consensus for early vaccination due to high risk or outbreak remains at **6 months of age**. - Administering it slightly before 6 months may still face issues with **maternal antibody interference**, potentially reducing efficacy. *Before 3 months* - Vaccinating this early is not recommended due to significant interference from **maternal antibodies**, which are still abundant in infants. - The infant's **immune system** is also less mature, leading to an even weaker response and decreased protection.

Q: Measles vaccination is given at -

9 months. ***9 months*** - The first dose of the **measles vaccine (MMR)** is typically administered at **9 months** of age in many national immunization programs. - This timing is chosen because maternal antibodies, which can interfere with vaccine effectiveness, generally wane by this age. *At birth* - Vaccines given at birth, such as **Hepatitis B** and **BCG**, target diseases with early exposure risks or have efficacy despite maternal antibodies. - Giving measles vaccine at birth would be ineffective due to the presence of **maternal antibodies** that neutralize the vaccine virus. *4 weeks* - This age is generally too early for measles vaccination as significant levels of **maternal antibodies** are often still present, which would reduce the vaccine's efficacy. - Other vaccines, like the rotavirus vaccine, might be given around this age, but not measles. *8 weeks* - While maternal antibodies might be decreasing, 8 weeks of age is still generally considered too early for optimal measles vaccine response. - Many primary vaccine series (e.g., DTaP, IPV, Hib) begin at 6-8 weeks, but measles is usually delayed further for better efficacy and seroconversion rates.

Question 1

Which vaccine is associated with a risk of encephalopathy?

Accepted Answer

Measles

Answer

OPV

Answer

Rubella

Answer

BCG

Question 2

Ideal temperature for DPT storage?

Accepted Answer

4 to 8°C

Answer

Room temperature

Answer

0 to - 20°C

Answer

None of the options

Question 3

Which of the following is the primary component of the AFP (Acute Flaccid Paralysis) case definition used in polio surveillance?

Accepted Answer

Onset of acute flaccid paralysis

Answer

All of the above

Answer

Stool specimen positive for poliovirus

Answer

Presence of residual paralysis after 60 days

Question 4

What is the appropriate diluent for the BCG vaccine?

Accepted Answer

Sterile distilled water

Answer

Sterile normal saline

Answer

Sterile dextrose solution

Answer

Colloid solutions

Question 5

Dukoral is:

Accepted Answer

Oral cholera vaccine

Answer

Oral rotavirus vaccine

Answer

Oral typhoid vaccine

Answer

Ready to use therapeutic food

Question 6

All following are at-risk group adults meriting Hepatitis B vaccination in low endemic areas except for which of the following?

Accepted Answer

Diabetics on insulin

Answer

Medical/nursing personnel

Answer

Patients with chronic liver disease

Answer

Patients on chronic hemodialysis

Question 7

What are the serogroups covered by the bivalent meningococcal vaccine?

Accepted Answer

Serogroup A and C

Answer

Serogroup A

Answer

Serogroup W

Answer

Serogroup C

Question 8

What is the standard amount of diphtheria toxoid in the DT vaccine?

Accepted Answer

30 Lf

Answer

5 Lf

Answer

10 Lf

Answer

15 Lf

Question 9

At what age can the measles vaccine be administered for the first time in high-risk scenarios or outbreak situations?

Accepted Answer

At 6 months

Answer

3 to 5 months

Answer

5 to 6 months

Answer

Before 3 months

Question 10

Measles vaccination is given at -

Accepted Answer

9 months

Answer

At birth

Answer

4 weeks

Answer

8 weeks

Immunization and Vaccine-Preventable Diseases — MCQs

Immunization and Vaccine-Preventable Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?